Exscientia (NASDAQ:EXAI) Stock Price Up 6.5%

Exscientia plc (NASDAQ:EXAI)’s stock price rose 6.5% during trading on Wednesday . The company traded as high as $5.48 and last traded at $5.43. Approximately 147,576 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 629,249 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reissued an “equal weight” rating and set a $7.00 target price on shares of Exscientia in a research note on Monday, April 22nd.

Exscientia Price Performance

The business has a fifty day simple moving average of $5.02 and a 200-day simple moving average of $5.64. The stock has a market capitalization of $649.16 million, a P/E ratio of -4.12 and a beta of 0.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30.

Exscientia (NASDAQ:EXAI) last issued its earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share (EPS) for the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. The company had revenue of $6.70 million for the quarter. Sell-side analysts expect that Exscientia plc will post -1.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

Several hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Exscientia by 112.1% in the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after buying an additional 2,302 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Exscientia by 359.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after buying an additional 4,104 shares during the last quarter. Walled Lake Planning & Wealth Management LLC purchased a new position in shares of Exscientia in the 4th quarter worth about $64,000. Colonial River Wealth Management LLC bought a new stake in Exscientia in the fourth quarter worth about $86,000. Finally, New Republic Capital LLC bought a new position in shares of Exscientia during the 4th quarter valued at approximately $128,000. Institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.